Patents Examined by Patricia L. Morris
  • Patent number: 11142524
    Abstract: Substituted -3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and related compounds, which are useful as inhibitors of ENPP1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the ENPP1.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: October 12, 2021
    Inventors: Hariprasad Vankayalapati, Sunil Sharma, Mohan Rao Kaadige, Alexis Weston, Trason Thode
  • Patent number: 11142501
    Abstract: Provided herein are novel monomethyl fumarate prodrugs.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: October 12, 2021
    Assignee: Ixchel Pharma, Inc.
    Inventor: Sundeep Dugar
  • Patent number: 11142511
    Abstract: The present invention relates to a coumarin (keto) oxime ester compound of formula (I), wherein n and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification. The compound has strong ultraviolet absorption in the range of 300 to 450 nm. After absorbing light energy, it can quickly transfer energy and continuously initiate polymerization. It has obvious advantages in terms of photosensitivity and pattern integrity, and is very suitable for radiation curing by UV-LED light source. In addition, the compound of formula (I) also has good thermal stability. The present invention also relates to a method for preparing the compound of formula (I) and use of the compound. The compound is suitable as a photoinitiator in a UV-LED light curing system and is suitable for the radiation wavelength of UV-LED light curing.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: October 12, 2021
    Assignee: Hubei Gurun Technology Co., Ltd.
    Inventors: Yulian Pang, Yingquan Zou, Shuheng Fan, Ming Gao, Yangyang Xin
  • Patent number: 11136318
    Abstract: The present disclosure relates to the preparation of methyl 2-(1H-indole-3-carbonyl)thiazole-4-carboxylate (ITE) and related compounds with high yield, purity, and scalability. The processes apply the use of a Weinreb amide intermediate as a scaffold for the preparation of ITE and structural analogs.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: October 5, 2021
    Assignee: Noramco, LLC
    Inventors: Martin Benedict Strack, Jasper Kaiser, Gnel Mkrtchyan, Wen-Chun Zhang
  • Patent number: 11136328
    Abstract: Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: October 5, 2021
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro
  • Patent number: 11136305
    Abstract: The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: October 5, 2021
    Assignee: R.J. Reynolds Tobacco Company
    Inventors: Gary M. Dull, Andrew Carr, Emma Sharp
  • Patent number: 11124480
    Abstract: A compound of formula (I), or an N-oxide thereof is provided. In the compound of formula (I), Het1 represents Het1-1, Het1-2, Het1-3, Het1-4, Het1-5, Het1-6, Het1-7, Het1-8, or Het1-9, and the remaining variable groups are as defined in the specification. The compound of formula (I), or N-oxide thereof has a superior effect in controlling arthropod pests.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: September 21, 2021
    Inventors: Kohei Orimoto, Takamasa Tanabe, Yoshihiko Nokura, Yuji Nakajima
  • Patent number: 11117869
    Abstract: Provided herein are 8-methyl-8-azabicyclo[3.2.1]octan-3-yl and pyridin-4-ylmethanyl ester and amide compounds and compositions. Also provided herein are methods of preventing or delaying the onset of myopia in a subject in need thereof, comprising administering the compounds or compositions provided herein to the subject. Also provided herein are methods of reducing or preventing the progression of myopia in a subject in need thereof, comprising administering the compounds or compositions provided herein to the subject.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: September 14, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Eric Carlson, Mitchell A. deLong, Heeren Gordhan, Cynthia L. Lichorowic, Jill M. Sturdivant
  • Patent number: 11111230
    Abstract: The present invention relates to a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, a method for inhibiting indoleamine 2,3-dioxygenase, and its use in medicine.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: September 7, 2021
    Inventors: Pan Li, Qiaodong Wen, Ji Wang, Quan Gan, Yang Lu, Donghui Yang
  • Patent number: 11111243
    Abstract: The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: September 7, 2021
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Chul Yu, Ming Yu, Manuel Zancanella, Zhe Li
  • Patent number: 11104661
    Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: August 31, 2021
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Matthew G. Bursavich, Dan Cui, James E. Dowling, Kristopher N. Hahn, Bryce A. Harrison, Fu-Yang Lin, Blaise S. Lippa, Bruce N. Rogers, Dawn M. Troast, Cheng Zhong, Kyle D. Konze, Aleksey I. Gerasyuto, Byungchan Kim, Salma Rafi, Tyler Day, Eugene Hickey, Evelyne Houang, Robert Zahler
  • Patent number: 11091436
    Abstract: The subject-matter of the invention is process for the separation of optical isomers of racemic 3-alk-3-carboxylic acid ethyl esters of formula rac-I with the resolving agent (II) (?)-2,3:4,5-di-O-izopropylidene-2-keto-L-gulonic acid (hereinafter: diacetone-L-ketogulonic acid).
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: August 17, 2021
    Inventors: Ferenc Faigl, Béla Mátravölgyi, Ágnes Mizsák
  • Patent number: 11091458
    Abstract: The present invention relates to a method of preparing racemic nicotine comprising: (i) reacting ethyl nicotinate and N-vinylpyrrolidone in the presence of an alcoholate base to 3-nicotinoyl-1-vinylpyrrolidin-2-one; (ii) reacting the 3-nicotinoyl-1-vinylpyrrolidin-2-one with an acid to myosmine; (iii) reducing the myosmine to nornicotine using a reducing agent; and (iv) methylating the nornicotine to obtain the racemic nicotine.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: August 17, 2021
    Assignees: Siegfried AG, Contraf-Nicotex-Tobacco GmbH
    Inventors: Beat Theodor Weber, Christian Lothschütz, Ben Pan
  • Patent number: 11091473
    Abstract: The invention relates to compounds of formula (I), compositions containing the same, and methods for treating and/or diminishing pain in a subject in need thereof. The compounds of formula (I) are effective for treating opioid-induced tachyphylaxis and opioid-induced hyperalgesia.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: August 17, 2021
    Assignee: Acadia Pharmaceuticals Inc.
    Inventors: Scott L. Dax, Pasquale N. Confalone
  • Patent number: 11084816
    Abstract: The anionic imide material is obtained by preparing a solution or a suspension of an imide compound, then reducing and drying the same; the anionic material comprises anions of an imide compound, the anions being at least one selected from the following formula I or formula II; in formula I or II: n=1, 2, or 3; R1, R2 are respectively selected from at least one of H, amino, carboxyl, hydroxy, thiol, and pyridyl groups; X1-X4 are respectively an electron withdrawing group, and specifically selected from one of H, F, Cl, Br, CN, and NO2 groups. The anionic material of the present invention has a Curie temperature larger than room temperature and ferromagnetism, and is an organic magnetic material; it may be used for preparing an organic magnetic material and/or an organic magnetic device.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: August 10, 2021
    Inventors: Dehua Hu, Qinglin Jiang, Yuguang Ma, Duokai Zhao, Jiang Zhang, Zhongquan Mao, Yao Yao
  • Patent number: 11072633
    Abstract: The present invention provides a compound having the structure: for use in combination with an anti-tuberculosis drug for treating a subject infected with M. tuberculosis.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 27, 2021
    Inventors: Nicole Sampson, Xinxin Yang, Tianao Yuan
  • Patent number: 11072589
    Abstract: A method for preparing 1,2,4-triazole includes using a fluoroborate aryl diazonium salt, a diazoester derivative and an organic nitrile as reaction substrates, a transition metal salt as a catalyst, and an inorganic base as an additive in a cyclization reaction. The method has the following characteristics: the reaction is economical; the substrate is universal; the post-functionalization is easy; the reaction conditions are mild; the reaction can be performed in air; the catalyst amount used is less; and the post-treatment is simple. Meanwhile, the raw materials, such as the reactants and the catalyst used, are inexpensive and easily available; the reaction composition is reasonable; no ligand is needed; there are less reaction steps; and only one step of reaction is required to obtain a high yield, meeting the requirements and directions of contemporary green chemistry and medicinal chemistry, being suitable for screening highly active 1,2,4-triazole drugs.
    Type: Grant
    Filed: October 11, 2020
    Date of Patent: July 27, 2021
    Inventors: Haiyan Li, Huihuang Li, Yaxiong Wang, Xiaobing Wan
  • Patent number: 11066366
    Abstract: Various fentanyl derivatives are described. The derivatives exhibit high binding affinity to opioid receptors, but also have decreased blood brain permeability as compared to standard fentanyl. This, the resulting derivatives can be less addictive than standard fentanyl. Methods of making such derivatives are also disclosed in this document.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: July 20, 2021
    Assignee: Allegheny-Singer Research Institute
    Inventors: Saadyah Averick, Ahmed Badr, Shaohua Li, Keith LeJeune
  • Patent number: 11064697
    Abstract: The present invention relates to compounds I wherein the variables are defined as given in the description and claims. The invention further relates to uses, processes and intermediates for compounds I.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: July 20, 2021
    Assignee: BASF SE
    Inventors: Wassilios Grammenos, Christian Winter, Bernd Mueller, Antje Wolf, Ana Escribano Cuesta, Erica Cambeis, Jan Klaas Lohmann, Thomas Grote, Manuel Kretschmer, Nadine Riediger, Ian Robert Craig, Christine Wiebe, Violeta Terterya-Seiser, Andreas Koch, Marcus Fehr
  • Patent number: 11059810
    Abstract: A pharmaceutically acceptable salt as a renal outer medullary potassium channel (ROMK) inhibitor, specifically an L-tartrate and a crystal form I and crystal form II thereof, is described. The pharmaceutically acceptable salt of the ROMK inhibitor, specifically the L-tartrate, has improved bioavailability and stability.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: July 13, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Qiyun Shao, Guaili Wu, Jun Feng